Boston Scientific gets deep brain stimulation CE mark; 3-D printing comes to ultra-thin materials;

@FierceMedDev: Researchers develop the first blood test to diagnose adult depression. Story | Follow @FierceMedDev

@MichaelGFierce: Vaxxas' nanopatch garners WHO support in search of polio vax application. FierceDrugDelivery story | Follow @MichaelGFierce

@VarunSaxena2: Drug delivery specialist Genisphere receives an additional $2M in funding. FierceDrugDelivery article | Follow @VarunSaxena2

@EmilyWFierce: Mainstay Medical CEO reveals company's path to market for its neuromodulation implant. More | Follow @EmilyWFierce

> Boston Scientific received a CE mark for its Vercise deep brain simulation treatment device to patients with tremors. Release

> Using an electronic nose, researchers at the University of Leicester, have figured out a way to sniff out traces of infectious diseases in patients feces. News

> The cost-effective manufacturing practice of 3-D printing ultra-thin layers of material is coming soon from Northeastern University researchers. Story

Biotech News

@FierceBiotech: Boehringer pairs its lung cancer drug with a vaccine in $600M tie-up with CureVac. News | Follow @FierceBiotech

@JohnCFierce: Am I missing something? If the FDA eviscerates the low-T market, restricting use, doesn't that destroy the prospects of , Clarus, etc.? | Follow @JohnCFierce

@DamianFierce: $NVO's eye on a Seattle expansion could be balm to local biotech as Amgen heads for the door. Article | Follow @DamianFierce

@EmilyMFierce: ICYMI: Check out these 7 notable academic-pharma alliances of 2014. Feature | Follow @EmilyMFierce

> Struggling Merck KGaA plans blockbuster R&D campaign for biosimilars, pact for PD-L1. Story

> Merck's weekly diabetes drug stacks up to blockbuster Januvia in Phase III. Report

> Oral low-T drugs in the pipeline face a showdown with the FDA. More

Pharma News

@FiercePharma: Now trending on FiercePharmaMarketing: First-to-market launch? Bonus--but double bonus if you're Big Pharma. Article | Follow @FiercePharma

@EricPFierce: Potentially bad news for Amphastar and its $155.7M deal if Sanofi makes insulin for Mannkind. More | Follow @EricPFierce

@CarlyHFierce: This week in FiercePharmaMarketing: Takeda lets 900 reps fly at obesity; AZ + James Van Der Beek = FluMist sales? More | Follow @CarlyHFierce

> Bayer brings $12.9B plastics spin-off to Big Pharma's slim-down party. Story

> Put a lid on 'Low-T' drug use, FDA panel advises, threatening AbbVie, Lilly meds. Article

> Real-world hep C patients drop off pricey Sovaldi, CVS study finds. More

Vaccines News

> Takeda reorg preps vaccines unit for emerging markets test. News

> 10 volunteers receive Glaxo Ebola vaccine with no adverse effects yet. Story

> Merck KGaA calls it quits on cancer vaccine--again. More

> Protein Sciences nabs stake in diabetes vax developer Diamyd. Story

> AstraZeneca sends James Van Der Beek 'camping' to promote FluMist Quadrivalent. Article

Pharma Manufacturing News

> More FDA issues arise for Hospira in India. News

> Novartis says more cuts coming for New York Diovan plant. More

> FDA procedural delay on Rytary gives Impax breathing room. Report

> Baxter issues recall, this time because antibacterial gets mixed in wrong carton. Story

> Partner Sanofi wants to produce the insulin to be used in MannKind's Afrezza. Article

Suggested Articles

Qiagen launched a one-stop shop compiling publicly available genomic data, scientific literature and phenotypic information on potential superbugs.

Adaptive Biotechnologies is planning a $200 million IPO to help power its sequencing tests aimed at the body’s immune system and related therapies.

Abbott’s new diabetes test provides A1c results in three minutes, allowing clinicians to develop care plans within a single office visit.